Vertex Pharmaceuticals (VRTX)
553.15
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 3rd, 5:35 AM EST
News & Press Releases
Vertex (VRTX) Q3 2026 Earnings Call Transcriptfool.com
Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly.
Via The Motley Fool · November 3, 2026
VRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlook
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 11.8% year on year t...
Via StockStory · November 3, 2026
Vertex Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURNAVX and PALSONIFY.
Chief Executive Officer and President Reshma Kewalramani sa
Via MarketBeat · November 2, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 Earnings: In-Line Revenue, Modest EPS Miss, Raised Guidance and Higher Spendingchartmill.com
Via Chartmill · November 2, 2026
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reactionfool.com
Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.
Via The Motley Fool · November 2, 2026
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 11.8% year on year...
Via StockStory · November 2, 2026
Vertex Reports Third Quarter 2026 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · November 2, 2026
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...
Via StockStory · October 31, 2026
3 large-cap stocks with solid fundamentals
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Via StockStory · October 30, 2026
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fallchartmill.com
Via Chartmill · October 29, 2026
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenuefool.com
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
Via The Motley Fool · October 27, 2026
I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Movefool.com
Here's how I'm staying calm as valuations hit record highs.
Via The Motley Fool · October 26, 2026
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter Morefool.com
The company's gene-editing-focused platform looks promising.
Via The Motley Fool · October 24, 2026
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.fool.com
Vertex is expanding beyond its cystic fibrosis franchise.
Via The Motley Fool · October 24, 2026
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase IIImarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.
Chief Executive Officer and President Reshm
Via MarketBeat · October 23, 2026
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · October 23, 2026
S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declineschartmill.com
Via Chartmill · October 21, 2026
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
Via The Motley Fool · October 20, 2026
Vertex Appoints Daniel Brennan to its Board of Directors
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific’s Executive Vice President, Chief Financial Officer, where he had responsibility for all global finance functions and corporate business development.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · October 20, 2026
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive Itfool.com
Buffett has warned about "gambling" in the market.
Via The Motley Fool · October 19, 2026
Where Will CRISPR Therapeutics Stock Be in 2030?fool.com
The company's expertise in gene editing could lead to more breakthroughs.
Via The Motley Fool · October 18, 2026
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.fool.com
Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.
Via The Motley Fool · October 18, 2026
1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...
Via StockStory · October 16, 2026
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disordersfool.com
Vertex Pharmaceuticals is showing that it isn't a one-trick pony.
Via The Motley Fool · October 15, 2026
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.
Via The Motley Fool · October 13, 2026